XOMA Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
124,058.00
38,301.00
20,606.00
53,530.00
14,596.00
13,343
Depreciation, Depletion & Amortization
2,575.00
1,856.00
1,532.00
769.00
304.00
30
Other Funds
-
-
-
-
890.00
3,651
Funds from Operations
48,713.00
71,247.00
29,718.00
53,477.00
10,883.00
9,662
Changes in Working Capital
2,798.00
7,035.00
1,174.00
19,788.00
8,197.00
2,982
Net Operating Cash Flow
45,915.00
78,282.00
30,892.00
33,689.00
2,686.00
12,644
Capital Expenditures
1,169.00
325.00
430.00
59.00
8.00
Sale of Fixed Assets & Businesses
-
-
4,880.00
49.00
1,614.00
Purchase/Sale of Investments
20,009.00
20,000.00
-
622.00
-
Net Investing Cash Flow
18,840.00
19,675.00
4,450.00
612.00
1,606.00
Issuance/Reduction of Debt, Net
3,125.00
5,917.00
13,319.00
6,999.00
17,581.00
Net Financing Cash Flow
83,389.00
35,560.00
13,801.00
6,942.00
13,258.00
Net Change in Cash
56,314.00
23,214.00
12,678.00
40,025.00
17,729.00
Free Cash Flow
47,084.00
78,607.00
31,322.00
33,748.00
2,678.00
Change in Capital Stock
86,514.00
41,477.00
482.00
57.00
31,729.00
Exchange Rate Effect
-
167.00
37.00
6.00
179.00

About XOMA

View Profile
Address
2200 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.xoma.com
Updated 07/08/2019
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J.